USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: XL SCI-TECH, INC.
City: RICHLAND
State: WA
Zip+4: 99354-1663
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,382,535.00 11
SBIR Phase II $2,052,425.00 3

Award List:

TIMED BIORESORBABLE Y 90 MICROSPHERES FOR RADIOTHERAPY

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peng, yongren b
Award Amount: $99,146.00

PRODUCTION OF Y90 MICROSPHERES FOR RADIATION THERAPY

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peng, Yongren B
Award Amount: $99,922.00

N/A

Award Year / Program / Phase: 1999 / SBIR / Phase II
Agency: HHS
Principal Investigator: Peng yongren b
Award Amount: $839,283.00

Production of Y-90 Microspheres for Radiation Therapy

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yongren B. Peng
Award Amount: $0.00
Abstract:
DESCRIPTION (Provided by Applicant): The feasibility of continuous and economical microfabrication of timed-bioresorbable glass microspheres containing yttrium-90 (Y-90) at therapeutic concentrations has been successfully demonstrated using Y-89… More

Production of Y-90 Microspheres for Radiation Therapy

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Yongren B. Peng
Award Amount: $420,423.00
Abstract:
DESCRIPTION (Provided by Applicant): The feasibility of continuous and economical microfabrication of timed-bioresorbable glass microspheres containing yttrium-90 (Y-90) at therapeutic concentrations has been successfully demonstrated using Y-89… More

TIMED-BIORESORBABLE RADIOSEEDS FOR PROSTATE CANCER

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yongren B. Peng
Award Amount: $108,863.00
Abstract:
Radioisotopes used for prostate cancer treatment are predominately photon/gamma-emitters (I-125, Pd-103, Ir-192). Both temporary and permanent gamma-emitting radioseeds have gained acceptance for interstitial implantation in the prostate. Due to greater tissue penetration, however, gamma radiation… More

CONTROLLED CELL MEMBRANE DISRUPTION:GENE TRANSFECTION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yongren B. Peng
Award Amount: $111,719.00
Abstract:
A cell population can be made amenable to the uptake of exogenous molecules by rupturing the plasma membranes of the cells. This allows the incorporation of the desired gene molecules into targeted cells. Over- rupturing of cell membranes will lead to undesirable loss of viability of the cell… More

Low Cost Manufacturing Process for Sodium Iodide Detectors

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency / Branch: DOD / DTRA
Principal Investigator: Y. B. Peng, President
Award Amount: $99,981.00
Abstract:
An unconventional, continuous, and flexible manufacturing process is proposed for the production of sodium iodide detectors. The steps of crystal growing and substantially simplified detector machining are integrated into one streamline process based on proven techniques with minimal capital… More

Absorbable and Low-Cost Radioseeds for Malignant Tumors

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yongren B. Peng
Award Amount: $146,461.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this Phase I research is to demonstrate the feasibility of creating timed-bioabsorbable Pd-103 seeds for the treatment of prostate tumors. Timed- bioabsorbable seeds have the combined benefits of titanium seeds, high dose rate temporary seeds,… More

Absorbable and Low-Cost Radioseeds for Malignant Tumors

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Yongren B. Peng
Award Amount: $792,719.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this Phase I research is to demonstrate the feasibility of creating timed-bioabsorbable Pd-103 seeds for the treatment of prostate tumors. Timed- bioabsorbable seeds have the combined benefits of titani um seeds, high dose rate temporary seeds,… More

Nano Radioisotope Sources For Targeted Radiation Therapy

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yongren B. Peng
Award Amount: $140,370.00
Abstract:
DESCRIPTION (provided by applicant): Radioisotopes used in targeted therapy are often labeled to targeting biomolecules. Different radioisotope and biomolecule usually require different linkage to bind the radioisotope to the targeting biomolecule. This pr oposed research is to create modular nano… More

PET Enabled Microspheres for Radioembolization of Liver Tumors

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yongren B. Peng – 509-375-0884
Award Amount: $191,356.00
Abstract:
DESCRIPTION (provided by applicant): Project Summary/Abstract Current radioembolic Y-90 microspheres have been generally recognized as the state-of-the-art for treating primary and metastatic liver tumors. However, the clinical results vary vastly dueto the lack of accurate diagnostic imaging… More

Enzyme Replacement Therapy for Sanfilippo A Lysosomal Rare Disease

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yongren B. Peng – 509-375-0884
Award Amount: $202,586.00
Abstract:
DESCRIPTION (provided by applicant): Current practice in the USA for inoperable esophageal cancer is a palliative treatment using metal stent for end-stage cancer patients. Outside the USA (especially in Far East countries including China and Korea), therehave been reported clinical benefits of… More

A Novel Brachytherapy Agent for GBM

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yongren B. Peng – 509-375-0884
Award Amount: $182,131.00
Abstract:
DESCRIPTION (provided by applicant): Molecularly Engineered Biomaterials for Minimally Invasive Dental Treatment Molecularly-engineered biomaterials are an ideal candidate for minimally invasive dental preparations, caries removal, and other dental treatments, including cleaning in perigingival… More